Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial

Trappe Ralf U.; Dierickx Daan; Zimmermann Heiner; Morschhauser Franck; Mollee Peter; Zaucha Jan M.; Dreyling Martin H.; Duehrsen Ulrich; Reinke Petra; Verhoef Gregor; Subklewe Marion; Huettmann Andreas; Tousseyn Thomas; Salles Gilles; Kliem Volker; Hauser Ingeborg A.; Tarella Corrado; Van Den Neste Eric; Gheysens Olivier; Anagnostopoulos Ioannis; Leblond Veronique; Riess Hanno; Choquet Sylvain

首页> 外文期刊>Journal of Clinical Oncology >Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial

【24h】

Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial

机译：对Rituximab诱导的反应是B细胞移植后淋巴抑制性疾病中的预测标志物，并在国际，前瞻性期II试验中成功分层或Rituximab或R-Checon Consolidation

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2017年第5期|共9页
作者
Trappe Ralf U.; Dierickx Daan; Zimmermann Heiner; Morschhauser Franck; Mollee Peter; Zaucha Jan M.; Dreyling Martin H.; Duehrsen Ulrich; Reinke Petra; Verhoef Gregor; Subklewe Marion; Huettmann Andreas; Tousseyn Thomas; Salles Gilles; Kliem Volker; Hauser Ingeborg A.; Tarella Corrado; Van Den Neste Eric; Gheysens Olivier; Anagnostopoulos Ioannis; Leblond Veronique; Riess Hanno; Choquet Sylvain;
展开▼
作者单位

DIAKO Evangel Diakonie Krankenhaus Bremen Bremen Germany;

Katholieke Univ Leuven Leuven Belgium;

DIAKO Evangel Diakonie Krankenhaus Bremen Bremen Germany;

Hop Claude Huriez Lille France;

Univ Queensland Brisbane Qld Australia;

Med Univ Gdansk Gdansk Poland;

Univ Munich Munich Germany;

Univ Duisburg Essen Essen Germany;

Charite Berlin Germany;

Katholieke Univ Leuven Leuven Belgium;

Univ Munich Munich Germany;

Univ Duisburg Essen Essen Germany;

Katholieke Univ Leuven Leuven Belgium;

Hosp Civils Lyon Pierre Benite France;

Nephrol Ctr Lower Saxony Munich Germany;

JW Goethe Univ Hosp Frankfurt Germany;

European Inst Oncol Milan Italy;

Clin Univ St Luc Brussels Belgium;

Katholieke Univ Leuven Leuven Belgium;

Charite Berlin Germany;

Univ Paris 06 Paris France;

Charite Berlin Germany;

Univ Paris 06 Paris France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial [J] . Trappe Ralf U., Dierickx Daan, Zimmermann Heiner, Journal of Clinical Oncology . 2017,第5期

机译：对Rituximab诱导的反应是B细胞移植后淋巴抑制性疾病中的预测标志物，并在国际，前瞻性期II试验中成功分层或Rituximab或R-Checon Consolidation
2. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease | Haematologica [J] . Eva González-Barca, Eva Domingo-Domenech, Francisco Javier Capote, Haematologica . 2007,第11期

机译：利妥昔单抗延长治疗B细胞移植后淋巴增生性疾病的前瞻性II期试验血液学
3. Successful Treatment of Rituximab-Resistant Epstein-Barr Virus-Associated Post-transplant Lymphoproliferative Disorder Using R-CHOP [J] . Takuro Kuriyama, Noriaki Kawano, Kiyoshi Yamashita, Journal of clinical and experimental hematopathology : . 2014,第2期

机译：使用R-CHOP成功治疗抗利妥昔单抗的爱泼斯坦-巴尔病毒相关的移植后淋巴细胞增生性疾病
4. Successful Treatment of a Patient With Epstein-Barr Virus–Positive B-Cell Lymphoproliferative Disorder Resembling Post-Transplant Lymphoproliferative Disorder Using Single-Agent Rituximab [O] . Norman I. Maldonado, Fernando Cabanillas, Elaine S. Jaffe, -1

机译：成功的治疗爱泼斯坦-巴尔病毒阳性的B细胞淋巴组织增生性疾病类似于使用单剂利妥昔单抗的移植后淋巴组织增生性疾病
5. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter Phase II trial [O] . Trappe, Ralf U., Dierickx, Daan, Zimmermann, Heiner, 2017

机译：对利妥昔单抗诱导的反应是B细胞移植后淋巴增生性疾病的一种预测标志物，并允许一项国际，前瞻性，多中心的II期临床试验成功地将其分为利妥昔单抗或r-chop合并

Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial

摘要

著录项

相似文献

相关主题

期刊订阅